Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials

Proteomics

Volumn 16, Issue 5, 2016, Pages 894-905

  Kirk, Jonathan A ^a   Holewinski, Ronald J ^b   Crowgey, Erin L ^c   Van Eyk, Jennifer E ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

Author keywords

Biomedicine; Cardiac; Clinical trials; Phosphodiesterase; Phosphorylation; Protein kinase G (PKG)

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

CLINICAL TRIAL (TOPIC); ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; HEART; HEART DISEASE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; BOVINE; DRUG DEVELOPMENT; HEART DISEASES; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; RAT;

AMINO ACID SEQUENCE; ANIMALS; CATTLE; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DRUG DISCOVERY; HEART; HEART DISEASES; HUMANS; MICE; RATS; SIGNAL TRANSDUCTION;

EID: 84959571844     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201500401     Document Type: Review

References (103)

1. Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K. et al., Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131, e29-e322.
2. Patel, C. B., Cowger, J. A., Zuckermann, A., A contemporary review of mechanical circulatory support. J. Heart Lung Transplant. 2014, 33, 667-674.
3. Kirk, J. A., Kass, D. A., Electromechanical dyssynchrony and resynchronization of the failing heart. Circ. Res. 2013, 113, 765-776.
4. McMurray, J. J., Packer, M., Desai, A. S., Gong, J. et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014, 371, 993-1004.
5. Sacks, C. A., Jarcho, J. A., Curfman, G. D., Paradigm shifts in heart-failure therapy-a timeline. N. Engl. J. Med. 2014, 371, 989-991.
6. Lee, D. I., Kass, D. A., Phosphodiesterases and cyclic GMP regulation in heart muscle. Physiology (Bethesda) 2012, 27, 248-258.
7. Tsai, E. J., Kass, D. A., Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther. 2009, 122, 216-238.
8. Takimoto, E., Champion, H. C., Li, M., Belardi, D. et al., Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 2005, 11, 214-222.
9. Redfield, M. M., Chen, H. H., Borlaug, B. A., Semigran, M. J. et al., Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. J. Am. Med. Assoc. 2013, 309, 1268-1277.
10. Sandberg, M., Natarajan, V., Ronander, I., Kalderon, D. et al., Molecular cloning and predicted full-length amino acid sequence of the type I beta isozyme of cGMP-dependent protein kinase from human placenta. Tissue distribution and developmental changes in rat. FEBS Lett. 1989, 255, 321-329.
11. Uhler, M. D., Cloning and expression of a novel cyclic GMP-dependent protein kinase from mouse brain. J. Biol. Chem. 1993, 268, 13586-13591.
12. Wernet, W., Flockerzi, V., Hofmann, F., The cDNA of the two isoforms of bovine cGMP-dependent protein kinase. FEBS Lett. 1989, 251, 191-196.
13. Francis, S. H., Woodford, T. A., Wolfe, L., Corbin, J. D., Types I alpha and I beta isozymes of cGMP-dependent protein kinase: alternative mRNA splicing may produce different inhibitory domains. Sec. Mess Phosphoprot. 1988, 12, 301-310.
14. Wolfe, L., Corbin, J. D., Francis, S. H., Characterization of a novel isozyme of cGMP-dependent protein kinase from bovine aorta. J. Biol. Chem. 1989, 264, 7734-7741.
15. Alverdi, V., Mazon, H., Versluis, C., Hemrika, W. et al., cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. J. Mol. Biol. 2008, 375, 1380-1393.
16. Burgoyne, J. R., Madhani, M., Cuello, F., Charles, R. L. et al., Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 2007, 317, 1393-1397.
17. Nakamura, T., Ranek, M. J., Lee, D. I., Shalkey Hahn, V. et al., Prevention of PKG1alpha oxidation augments cardioprotection in the stressed heart. J. Clin. Invest. 2015, 125, 2468-2472.
18. Pinkse, M. W., Uitto, P. M., Hilhorst, M. J., Ooms, B., Heck, A. J., Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. Anal. Chem. 2004, 76, 3935-3943.
19. Feil, R., Kellermann, J., Hofmann, F., Functional cGMP-dependent protein kinase is phosphorylated in its catalytic domain at threonine-516. Biochemistry 1995, 34, 13152-13158.
20. Hou, Y., Lascola, J., Dulin, N. O., Ye, R. D., Browning, D. D., Activation of cGMP-dependent protein kinase by protein kinase C. J. Biol. Chem. 2003, 278, 16706-16712.
21. Busch, J. L., Bessay, E. P., Francis, S. H., Corbin, J. D., A conserved serine juxtaposed to the pseudosubstrate site of type I cGMP-dependent protein kinase contributes strongly to autoinhibition and lower cGMP affinity. J. Biol. Chem. 2002, 277, 34048-34054.
22. Dey, N. B., Busch, J. L., Francis, S. H., Corbin, J. D., Lincoln, T. M., Cyclic GMP specifically suppresses Type-Ialpha cGMP-dependent protein kinase expression by ubiquitination. Cell Signal. 2009, 21, 859-866.
23. Vallur, R., Kalbacher, H., Feil, R., Catalytic activity of cGMP-dependent protein kinase type I in intact cells is independent of N-terminal autophosphorylation. PLoS One 2014, 9, e98946.
24. Lundby, A., Lage, K., Weinert, B. T., Bekker-Jensen, D. B. et al., Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep. 2012, 2, 419-431.
25. Vaandrager, A. B., Ehlert, E. M., Jarchau, T., Lohmann, S. M., de Jonge, H. R., N-terminal myristoylation is required for membrane localization of cGMP-dependent protein kinase type II. J. Biol. Chem. 1996, 271, 7025-7029.
26. Castro, L. R., Verde, I., Cooper, D. M., Fischmeister, R., Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006, 113, 2221-2228.
27. Tegge, W., Frank, R., Hofmann, F., Dostmann, W. R., Determination of cyclic nucleotide-dependent protein kinase substrate specificity by the use of peptide libraries on cellulose paper. Biochemistry 1995, 34, 10569-10577.
28. Molkentin, J. D., Lu, J. R., Antos, C. L., Markham, B. et al., A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93, 215-228.
29. Houser, S. R., Piacentino, V., 3rd, Weisser, J., Abnormalities of calcium cycling in the hypertrophied and failing heart. J. Mol. Cell. Cardiol. 2000, 32, 1595-1607.
30. Wehrens, X. H., Lehnart, S. E., Marks, A. R., Intracellular calcium release and cardiac disease. Annu. Rev. Physiol. 2005, 67, 69-98.
31. Fiedler, B., Lohmann, S. M., Smolenski, A., Linnemuller, S. et al., Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc. Natl. Acad. Sci. USA 2002, 99, 11363-11368.
32. Yang, L., Liu, G., Zakharov, S. I., Bellinger, A. M. et al., Protein kinase G phosphorylates Cav1.2 alpha1c and beta2 subunits. Circ. Res. 2007, 101, 465-474.
33. Takahashi, E., Abe, J., Gallis, B., Aebersold, R. et al., p90(RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1. J. Biol. Chem. 1999, 274, 20206-20214.
34. Perez, N. G., Piaggio, M. R., Ennis, I. L., Garciarena, C. D. et al., Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 2007, 49, 1095-1103.
35. Yeves, A. M., Garciarena, C. D., Nolly, M. B., Chiappe de Cingolani, G. E. et al., Decreased activity of the Na+/H+ exchanger by phosphodiesterase 5A inhibition is attributed to an increase in protein phosphatase activity. Hypertension 2010, 56, 690-695.
36. Nakamura, T. Y., Iwata, Y., Arai, Y., Komamura, K., Wakabayashi, S., Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ. Res. 2008, 103, 891-899.
37. Kuwahara, K., Wang, Y., McAnally, J., Richardson, J. A. et al., TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 2006, 116, 3114-3126.
38. Nishida, M., Watanabe, K., Sato, Y., Nakaya, M. et al., Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition. J. Biol. Chem. 2010, 285, 13244-13253.
39. Koitabashi, N., Aiba, T., Hesketh, G. G., Rowell, J. et al., Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J. Mol. Cell. Cardiol. 2010, 48, 713-724.
40. Huang, J., Zhou, H., Mahavadi, S., Sriwai, W., Murthy, K. S., Inhibition of Galphaq-dependent PLC-beta1 activity by PKG and PKA is mediated by phosphorylation of RGS4 and GRK2. Am. J. Physiol. Cell Physiol. 2007, 292, C200-C208.
41. Tokudome, T., Kishimoto, I., Horio, T., Arai, Y. et al., Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008, 117, 2329-2339.
42. Takimoto, E., Koitabashi, N., Hsu, S., Ketner, E. A. et al., Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 2009, 119, 408-420.
43. Klaiber, M., Kruse, M., Volker, K., Schroter, J. et al., Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2. Basic Res. Cardiol. 2010, 105, 583-595.
44. Bujak, M., Frangogiannis, N. G., The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74, 184-195.
45. Shi, Y., Massague, J., Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113, 685-700.
46. Massague, J., TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 67, 753-791.
47. Li, P., Wang, D., Lucas, J., Oparil, S. et al., Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ. Res. 2008, 102, 185-192.
48. Zhang, M., Takimoto, E., Hsu, S., Lee, D. I. et al., Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J. Am. Coll. Cardiol. 2010, 56, 2021-2030.
49. Solaro, R. J., Moir, A. J., Perry, S. V., Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature 1976, 262, 615-617.
50. Yuasa, K., Michibata, H., Omori, K., Yanaka, N., A novel interaction of cGMP-dependent protein kinase I with troponin T. J. Biol. Chem. 1999, 274, 37429-37434.
51. Hajjar, R. J., Schwinger, R. H., Schmidt, U., Kim, C. S. et al., Myofilament calcium regulation in human myocardium. Circulation 2000, 101, 1679-1685.
52. Pfitzer, G., Ruegg, J. C., Flockerzi, V., Hofmann, F., cGMP-dependent protein kinase decreases calcium sensitivity of skinned cardiac fibers. FEBS Lett. 1982, 149, 171-175.
53. Layland, J., Li, J. M., Shah, A. M., Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J. Physiol. 2002, 540, 457-467.
54. Lee, D. I., Vahebi, S., Tocchetti, C. G., Barouch, L. A. et al., PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res. Cardiol. 2010, 105, 337-347.
55. Jin, C. Z., Jang, J. H., Kim, H. J., Wang, Y. et al., Myofilament Ca2+ desensitization mediates positive lusitropic effect of neuronal nitric oxide synthase in left ventricular myocytes from murine hypertensive heart. J. Mol. Cell. Cardiol. 2013, 60, 107-115.
56. Linke, W. A., Hamdani, N., Gigantic business: titin properties and function through thick and thin. Circ. Res. 2014, 114, 1052-1068.
57. Sharma, K., Kass, D. A., Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ. Res. 2014, 115, 79-96.
58. Kruger, M., Kotter, S., Grutzner, A., Lang, P. et al., Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res. 2009, 104, 87-94.
59. Kotter, S., Gout, L., Von Frieling-Salewsky, M., Muller, A. E. et al., Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc. Res. 2013, 99, 648-656.
60. Kruger, M., Linke, W. A., Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. J. Muscle Res. Cell Motil. 2006, 27, 435-444.
61. Hidalgo, C., Hudson, B., Bogomolovas, J., Zhu, Y. et al., PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ. Res. 2009, 105, 631-638.
62. Das, A., Salloum, F. N., Xi, L., Rao, Y. J., Kukreja, R. C., ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H1236-H1243.
63. Cheng, H., Woodgett, J., Maamari, M., Force, T., Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J. Mol. Cell. Cardiol. 2011, 51, 607-613.
64. Hirotani, S., Zhai, P., Tomita, H., Galeotti, J. et al., Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ. Res. 2007, 101, 1164-1174.
65. Kirk, J. A., Holewinski, R. J., Kooij, V., Agnetti, G. et al., Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3beta. J. Clin. Invest. 2014, 124, 129-138.
66. Guilluy, C., Sauzeau, V., Rolli-Derkinderen, M., Guerin, P. et al., Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br. J. Pharmacol. 2005, 146, 1010-1018.
67. Chau, V. Q., Salloum, F. N., Hoke, N. N., Abbate, A., Kukreja, R. C., Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am. J. Physiol. Heart Circ. Physiol. 2011, 300, H2272-H2279.
68. Agnetti, G., Halperin, V. L., Kirk, J., Chakir, K. et al., Desmin modifications associate with amyloid oligomers deposition in heart failure. Cardiovasc. Res. 2014, 102, 24-34.
69. Ranek, M. J., Terpstra, E. J., Li, J., Kass, D. A., Wang, X., Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation 2013, 128, 365-376.
70. Ranek, M. J., Kost, C. K., Jr., Hu, C., Martin, D. S., Wang, X., Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner. J. Mol. Cell. Cardiol. 2014, 69, 43-51.
71. McLendon, P. M., Robbins, J., Proteotoxicity and cardiac dysfunction. Circ. Res. 2015, 116, 1863-1882.
72. Lewis, G. D., Lachmann, J., Camuso, J., Lepore, J. J. et al., Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115, 59-66.
73. Guazzi, M., Tumminello, G., Di Marco, F., Fiorentini, C., Guazzi, M. D., The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J. Am. Coll. Cardiol. 2004, 44, 2339-2348.
74. Bishu, K., Hamdani, N., Mohammed, S. F., Kruger, M. et al., Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 2011, 124, 2882-2891.
75. Hamdani, N., Bishu, K. G., von Frieling-Salewsky, M., Redfield, M. M., Linke, W. A., Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc. Res. 2013, 97, 464-471.
76. van Heerebeek, L., Hamdani, N., Falcao-Pires, I., Leite-Moreira, A. F. et al., Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012, 126, 830-839.
77. Hamdani, N., Franssen, C., Lourenco, A., Falcao-Pires, I. et al., Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ. Heart Fail. 2013, 6, 1239-1249.
78. Guazzi, M., Bandera, F., Forfia, P., Sildenafil and exercise capacity in heart failure. J. Am. Med. Assoc. 2013, 310, 432.
79. Redfield, M. M., Borlaug, B. A., Sildenafil and exercise capacity in heart failure-in reply. J. Am. Med. Assoc. 2013, 310, 432-433.
80. Nagayama, T., Hsu, S., Zhang, M., Koitabashi, N. et al., Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J. Mol. Cell. Cardiol. 2009, 46, 560-567.
81. Carnicer, R., Crabtree, M. J., Sivakumaran, V., Casadei, B., Kass, D. A., Nitric oxide synthases in heart failure. Antioxid. Redox. Signal. 2013, 18, 1078-1099.
82. Lee, D. I., Zhu, G., Sasaki, T., Cho, G. S. et al., Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 2015, 519, 472-476.
83. Gheorghiade, M., Marti, C. N., Sabbah, H. N., Roessig, L. et al., Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail. Rev. 2013, 18, 123-134.
84. Gissi, H. F. I., Tavazzi, L., Maggioni, A. P., Marchioli, R. et al., Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, 1223-1230.
85. Chen, J., Shearer, G. C., Chen, Q., Healy, C. L. et al., Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011, 123, 584-593.
86. Andersson, L., Porath, J., Isolation of phosphoproteins by immobilized metal (Fe3+) affinity chromatography. Anal. Biochem. 1986, 154, 250-254.
87. Villen, J., Beausoleil, S. A., Gerber, S. A., Gygi, S. P., Large-scale phosphorylation analysis of mouse liver. Proc. Natl. Acad. Sci. USA 2007, 104, 1488-1493.
88. Larsen, M. R., Thingholm, T. E., Jensen, O. N., Roepstorff, P., Jorgensen, T. J., Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell. Proteomics 2005, 4, 873-886.
89. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B. et al., Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127, 635-648.
90. Krause, M., Dent, E. W., Bear, J. E., Loureiro, J. J., Gertler, F. B., Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu. Rev. Cell Dev. Biol. 2003, 19, 541-564.
91. Degerman, E., Belfrage, P., Manganiello, V. C., Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem. 1997, 272, 6823-6826.
92. Rosman, G. J., Martins, T. J., Sonnenburg, W. K., Beavo, J. A. et al., Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3', 5'-cyclic nucleotide phosphodiesterase. Gene 1997, 191, 89-95.
93. Sasaki, H., Nagayama, T., Blanton, R. M., Seo, K. et al., PDE5 inhibitor efficacy is estrogen dependent in female heart disease. J. Clin. Invest. 2014, 124, 2464-2471.
94. Huang, S. Y., Tsai, M. L., Chen, G. Y., Wu, C. J., Chen, S. H., A systematic MS-based approach for identifying in vitro substrates of PKA and PKG in rat uteri. J. Proteome Res. 2007, 6, 2674-2684.
95. Bauer, A., Kuster, B., Affinity purification-mass spectrometry. Powerful tools for the characterization of protein complexes. Eur. J. Biochem. 2003, 270, 570-578.
96. Daub, H., Godl, K., Brehmer, D., Klebl, B., Muller, G., Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay Drug Dev. Technol. 2004, 2, 215-224.
97. Dirksen, E. H., Pinkse, M. W., Rijkers, D. T., Cloos, J. et al., Investigating the dynamic nature of the interactions between nuclear proteins and histones upon DNA damage using an immobilized peptide chemical proteomics approach. J. Proteome Res. 2006, 5, 2380-2388.
98. Kim, E., Park, J. M., Identification of novel target proteins of cyclic GMP signaling pathways using chemical proteomics. J. Biochem. Mol. Biol. 2003, 36, 299-304.
99. Scholten, A., Poh, M. K., van Veen, T. A., van Breukelen, B. et al., Analysis of the cGMP/cAMP interactome using a chemical proteomics approach in mammalian heart tissue validates sphingosine kinase type 1-interacting protein as a genuine and highly abundant AKAP. J. Proteome Res. 2006, 5, 1435-1447.
100. Casteel, D. E., Smith-Nguyen, E. V., Sankaran, B., Roh, S. H. et al., A crystal structure of the cyclic GMP-dependent protein kinase Idimerization/docking domain reveals molecular details of isoform-specific anchoring. J. Biol. Chem. 2010, 285, 32684-32688.
101. Huang, G. Y., Kim, J. J., Reger, A. S., Lorenz, R. et al., Structural basis for cyclic-nucleotide selectivity and cGMP-selective activation of PKG I. Structure 2014, 22, 116-124.
102. Saito, R., Smoot, M. E., Ono, K., Ruscheinski, J. et al., A travel guide to Cytoscape plugins. Nat. Methods 2012, 9, 1069-1076.
103. Maere, S., Heymans, K., Kuiper, M., BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005, 21, 3448-3449.